Bionek Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.22 M
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 467.68%
- Profit Growth 114.87%
- Ebitda 670.05%
- Net Worth 115.76%
- Total Assets 126.13%
About Bionek Pharmaceuticals
Bionek Pharmaceuticals Private Limited (BPPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 September 2020 (Four years and four months 19 days old ). Its registered office is in Varanasi, Uttar Pradesh, India.
The Company is engaged in the Non-Profit Organizations Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.22 M, as per Ministry of Corporate Affairs (MCA) records.
Abdul Ansari, Reyaz Ansari, Faiyaz Ahmed, and One other member serve as directors at the Company.
Company Details
-
Location
Varanasi, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U85300UP2020PTC135361
-
Company No.
135361
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
29 Sep 2020
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Bionek Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abdul Ansari
|
Managing Director | 29-Sep-2020 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Reyaz Ansari
|
Director | 25-May-2022 | Current |
|
Faiyaz Ahmed
|
Director | 29-Sep-2020 | Current |
|
Iftekhar Ahmad
|
Director | 29-Sep-2020 | Current |
Financial Performance of Bionek Pharmaceuticals.
Bionek Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 467.68% increase. The company also saw a substantial improvement in profitability, with a 114.87% increase in profit. The company's net worth Soared by an impressive increase of 115.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bionek Pharmaceuticals?
Unlock access to Bionek Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bionek Pharmaceuticals?
Bionek Pharmaceuticals has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bionek Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bionek Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
